Literature DB >> 7598738

Purification of recombinant human N-acetyltransferase type 1 (NAT1) expressed in E. coli and characterization of its potential role in folate metabolism.

A Ward1, M J Summers, E Sim.   

Abstract

Human arylamine N-acetyltransferase type 1 (NAT1) has been cloned from human genomic DNA, into the vector pET(5a) and expressed in Escherichia coli. The recombinant protein has been purified to apparent homogeneity using anion exchange chromatography. The arylamine acceptor specificity, and the effect of potential NAT1 inhibitors has been investigated using purified recombinant protein. The Km of the recombinant NAT1 protein for the substrates para-aminobenzoate (p-aba) and 4-aminosalicylate are 14.3 and 11.8 microM, respectively. Folate and amethopterin were found to be potent competitive inhibitors of p-aba acetylation, with Ki values of 13.3 and 9.5 microM, respectively. The pteroate moiety of folate, in contrast is a poor inhibitor, with 100 microM pteroate inhibiting only 40% of NAT1 activity. A catabolite of folate para-aminobenzoly-L-glutamate has also been shown to be a NAT1 substrate with a Km value of 263 microM.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7598738     DOI: 10.1016/0006-2952(95)00087-g

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  17 in total

1.  Loss of function polymorphisms in NAT1 protect against spina bifida.

Authors:  Liselotte E Jensen; Karen Hoess; Laura E Mitchell; Alexander S Whitehead
Journal:  Hum Genet       Date:  2006-05-06       Impact factor: 4.132

2.  Over-expression, purification, and characterization of recombinant human arylamine N-acetyltransferase 1.

Authors:  Haiqing Wang; Gregory M Vath; Akane Kawamura; Caleb A Bates; Edith Sim; Patrick E Hanna; Carston R Wagner
Journal:  Protein J       Date:  2005-02       Impact factor: 2.371

Review 3.  Environmental mechanisms of orofacial clefts.

Authors:  Michael A Garland; Kurt Reynolds; Chengji J Zhou
Journal:  Birth Defects Res       Date:  2020-10-30       Impact factor: 2.344

4.  Arylamine N-acetyltransferase responsible for acetylation of 2-aminophenols in Streptomyces griseus.

Authors:  Hirokazu Suzuki; Yasuo Ohnishi; Sueharu Horinouchi
Journal:  J Bacteriol       Date:  2006-12-08       Impact factor: 3.490

5.  Genomic organization of human arylamine N-acetyltransferase Type I reveals alternative promoters that generate different 5'-UTR splice variants with altered translational activities.

Authors:  Neville J Butcher; Ajanthy Arulpragasam; Hui Li Goh; Tamara Davey; Rodney F Minchin
Journal:  Biochem J       Date:  2005-04-01       Impact factor: 3.857

6.  Elucidation of xenobiotic metabolism pathways in human skin and human skin models by proteomic profiling.

Authors:  Sven van Eijl; Zheying Zhu; John Cupitt; Magdalena Gierula; Christine Götz; Ellen Fritsche; Robert J Edwards
Journal:  PLoS One       Date:  2012-07-26       Impact factor: 3.240

7.  Ocular defects associated with a null mutation in the mouse arylamine N-acetyltransferase 2 gene.

Authors:  Larissa Wakefield; Hilary Long; Nathan Lack; Edith Sim
Journal:  Mamm Genome       Date:  2007-05-09       Impact factor: 2.957

8.  Identification of a minimal promoter sequence for the human N-acetyltransferase Type I gene that binds AP-1 (activator protein 1) and YY-1 (Yin and Yang 1).

Authors:  Neville J Butcher; Ajanthy Arulpragasam; Catherine Pope; Rodney F Minchin
Journal:  Biochem J       Date:  2003-12-01       Impact factor: 3.857

9.  Structure and transcriptional regulation of the Nat2 gene encoding for the drug-metabolizing enzyme arylamine N-acetyltransferase type 2 in mice.

Authors:  Sotiria Boukouvala; Naomi Price; Kathryn E Plant; Edith Sim
Journal:  Biochem J       Date:  2003-11-01       Impact factor: 3.857

10.  N-Acetyltransferase 1 (NAT1) Genotype: A Risk Factor for Urinary Bladder Cancer in a Lebanese Population.

Authors:  Ibrahim A Yassine; Loulou Kobeissi; Michel E Jabbour; Hassan R Dhaini
Journal:  J Oncol       Date:  2012-08-22       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.